title: Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Carvalho
authors.forename: Paula
authors.initials: P
authors.lastname: Maio
authors.forename: Daniela
authors.initials: D
authors.lastname: Cunha
authors.forename: Isabel
authors.initials: I
authors.lastname: Freitas
authors.forename: Ana
authors.initials: A
authors.lastname: Afonso
authors.forename: Jorge
authors.initials: J
authors.lastname: Cardoso
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018951:Antigens, CD20; D001323:Autoantibodies / Q000276:immunology*; D051183:Desmoglein 1 / Q000276:immunology*; D051184:Desmoglein 3 / Q000276:immunology*; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D010392:Pemphigus / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001323:Autoantibodies; D051183:Desmoglein 1; D051184:Desmoglein 3; D007155:Immunologic Factors; D000069283:Rituximab